Prospect Biosystems, Inc. engages in the development, manufacturing, and marketing of instrumentation, reagents, consumables, and assays for bioanalytical research and molecular pathology. Prospect’s proprietary Edge™ technology provides a powerful tool to enhance and accelerate life sciences research, pharmaceutical product development, clinical and molecular diagnostics and pathology.

Edge™ platform is a breakthrough bioanalytical fractionation and separation technology that allows scientists, researchers, medical experts, including physicians and surgeons, involved in:

• Biomarker Discovery to rapidly characterize differences between diseased and healthy tissue

• Clinical Diagnostics to easily identify and evaluate predictive, diagnostic and prognostic disease biomarkers

• Clinical Trials to accelerate and improve outcome prediction through use of surrogate biomarkers

• Molecular Pathology to facilitate outcome prediction through use of tissue biomarkers

• Analytical Proteomics to significantly enrich low-abundance proteins from their crude cell or tissue extracts

Prospect ... “Outlook for future success”